MDRIpred: A webserver for predicting inhibitor against drug tolrent M.Tuberculosis
Home MDRIpred    |   Submit Molecule    |   Algorithm    |   DataSets    |   Help Page   |   Developers    |   Contact   

Inhibitor Prediction

  KiDoQ (Mtb target)

  GDoQ (Mtb target)

  ABMpred (Mtb target)

  eBooster (Mtb target)

  MDRIpred (Mtb cell)

  CancerIN (Cancer)

  ntEGFR (Cancer EGFR)

  EGFRpred (Cancer EGFR)

  DiPCell (Pancreatic Cancer)

  DMKPred (Human Kinases)

  TLR4HI (Human TLR4)

  HIVFin (HIV)

Antigenic Properties

ADMET Properties

  MetaPred (Cytochrome P450)

  ToxiPred (Aqueous toxicity)

  DrugMint (Drug-like)

  QED (Oral drug-like)

  Format Conversion



** Please cite "Singla et al., (2013) Designing of inhibitors against drug tolerant Mycobacterium tuberculosis (H37Rv). Chemistry Central Journal 7:49 **

Welcome to MDRIpred

M.tuberculosis (M.tb) an intracellular pathogen kills ~1.7 million people every year. Currently available antitubercular therapy shows limited success due to evolution of drug resistant strains as well as prolonged treatment time. The pathogenic cycle of tuberculosis comprises of i) activation or replicative phase, ii) latent or non-replicative phase and iii) reactivation phase. Since the behaviour of compounds is different in different physiological conditions, therefore it is important to design inhibitors against different phase of drug tolrent tuberculosis.

This open source server has been developed to provide service to scientific community working in the field of drug design against drug resistant M. Tuberculosis. This server allows uses to predict inhibitors against drug-tolerant M.tb H37Rv in different phase like replicate, non-replicative phase.